

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
MD	AA	4,454,106	Gansow et al.	June 12, 1984			
	AB	4,472,509	Gansow et al.	September 18, 1984			
	AC	4,814,275	Durda et al.	March 21, 1989			
	AD	4,855,353	Kurami et al.	August 8, 1989			
	AE	4,863,851	McEwan et al.	September 5, 1989			
	AF	4,863,854	Mattes et al.	September 5, 1989			
	AG	4,885,363	Tweedle et al.	December 5, 1989			
	AH	5,013,645	Kim	May 7, 1991			
	AI	5,053,503	Dean et al.	October 1, 1991			
	AJ	5,057,302	Johnson et al.	October 15, 1991			
	AK	5,118,611	Smith et al.	June 2, 1992			
	AL	5,130,118	Johnson et al.	July 14, 1992			
	AM	5,162,504	Horoszewicz	November 10, 1992			
	AN	5,198,208	Berg et al.	March 30, 1993			
	AO	5,208,324	Klaveness et al.	May 4, 1993			
	AP	5,217,704	Johnson et al.	June 8, 1993			
	AQ	5,227,471	Wright, Jr.	July 13, 1993			
	AR	5,229,289	Kjeldsen et al.	July 20, 1993			
	AS	5,314,996	Wright, Jr.	May 24, 1994			
	AT	5,342,924	Chang	August 30, 1994			
	AU	5,419,893	Berg et al.	May 30, 1995			
	AV	5,474,756	Tweedle et al.	December 12, 1995			
	AW	5,489,525	Pastan	February 6, 1996			
	AX	5,531,978	Berg et al.	July 2, 1996			
	AY	5,538,866	Israeli et al.	July 23, 1996			
	AZ	5,565,562	Parker et al.	October 15, 1996			

Examiner Signature	/Minh Tam Davis/ (08/18/2006)	Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 10448-201001	Application No. 10/736,112
	Applicant Jeffrey S. Ross			
	Filing Date December 15, 2003		Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
MD	AAA	5,578,484	Horoszewicz	November 26, 1996			
	ABB	5,599,677	Dowell et al.	February 4, 1997			
	ACC	5,639,879	Mease et al.	June 17, 1997			
	ADD	5,660,827	Thorpe et al.	August 26, 1997			
	AEE	5,674,470	Tweedle et al.	October 7, 1997			
	AFF	5,697,902	Goldenberg	December 16, 1997			
	AGG	5,763,202	Horoszewicz	June 9, 1998			
	AHH	5,776,427	Thorpe et al.	July 7, 1998			
	AII	5,804,602	Slusher et al.	September 8, 1998			
	AJJ	5,846,519	Tweedle et al.	December 8, 1998			
	AKK	5,855,866	Thorpe et al.	January 5, 1999			
	ALL	5,863,538	Thorpe et al.	January 26, 1999			
	AMM	5,877,289	Thorpe et al.	March 2, 1999			
	ANN	5,935,818	Israeli et al.	August 10, 1999			
	AOO	5,958,474	Lee et al.	September 28, 1999			
	APP	5,965,132	Thorpe et al.	October 12, 1999			
	AQQ	6,004,554	Thorpe et al.	December 21, 1999			
	ARR	6,004,555	Thorpe et al.	December 21, 1999			
	ASS	6,022,524	Maisano et al.	February 8, 2000			
	ATT	6,036,955	Thorpe et al.	March 14, 2000			
	AUU	6,051,230	Thorpe et al.	April 18, 2000			
	AVV	6,093,399	Thorpe et al.	July 25, 2000			
	AWW	6,107,090	Bander	August 22, 2000			
	AXX	6,136,311	Bander	October 24, 2000			
	AYY	6,143,274	Tweedle et al.	November 17, 2000			
	AZZ	6,150,508	Murphy et al.	November 21, 2000			
	AAAA	6,261,535	Thorpe et al.	July 17, 2001			

Examiner Signature /Minh Tam Davis/ (08/18/2006)	Date Considered 2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit
(37 CFR §1.98(b))			

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
MD	ABBB	6,331,175	Goldenberg	December 18, 2001			
MD	ACCC	6,649,163	Bander	November 18, 2003			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
MD	ADDD	WO 86/06384	11/ 1986	PCT				
	AEEE	WO 88/02635	04/ 1988	PCT				
	AFFF	WO 89/00557	01/ 1989	PCT				
	AGGG	WO 89/06979	08/ 1989	PCT				
	AHHH	WO 91/15466	10/ 1991	PCT				
	AIHH	WO 93/17715	09/ 1993	PCT				
	AJJJ	WO 93/19668	10/ 1993	PCT				
	AKKK	WO 94/04702	03/ 1994	PCT				
	ALLL	WO 94/09820	05/ 1994	PCT				
	AMMM	WO 94/26297	11/ 1994	PCT				
	ANNN	WO 95/26206	10/ 1995	PCT				
	AOOO	WO 95/31444	11/ 1995	PCT				
	APPP	WO 96/26272	08/ 1996	PCT				
	AQQQ	WO 96/39185	12/ 1996	PCT				
	ARRR	WO 96/40245	12/ 1996	PCT				
	ASSS	WO 97/32862	09/ 1997	PCT				
	ATTT	WO 97/35616	10/ 1997	PCT				
	AUUU	WO 99/43710	09/ 1999	PCT				
	AVVV	WO 00/50457	08/ 2000	PCT				
	AWWW	WO 00/52473	09/ 2000	PCT				
	AXXX	WO 00/74729	12/ 2000	PCT				

Examiner Signature /Minh Tam Davis/ (08/18/2006)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
MD	AYYY	EP 0 208 531 B1	01/ 1987	Europe				
	AZZZ	EP 0 232 751 B1	08/ 1987	Europe				
	AAAAA	EP 0 233 619 B1	08/ 1987	Europe				
	ABBBB	EP 0 279 397 B1	08/ 1988	Europe				
	ACCCC	EP 0 292 689 B1	11/ 1988	Europe				
	ADDDD	EP 0 299 795 A1	01/ 1989	Europe				
	AEEEE	EP 0 315 188 B1	05/ 1989	Europe				
	AFFFF	EP 0 382 583 B1	08/ 1990	Europe				
	AGGGG	EP 0 392 423 A2	10/ 1990	Europe				
	AHHHH	EP 0 466 200 A1	01/ 1992	Europe				
	AIIII	EP 0 594 739 B1	05/ 1994	Europe				
	AJJJJ	EP 0 882 454 A2	12/ 1998	Europe				
↓	AKKKK	NZ333683	01/2002	New Zealand				


Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MD	ALLLL	ATCC Deposit #HB9131 from June 24, 1986 (NOT AVAILABLE)
	AMMMM	Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prostate 30(1):65-68.
	ANNNN	Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-753.
	AOOOO	Chang et al. (1999), "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature", Cancer Research, 59(13):3192-3198.
↓	APPPP	Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).

Examiner Signature	/Minh Tam Davis/ (08/18/2006)	Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 10448-201001	Application No. 10/736,112
	Applicant Jeffrey S. Ross			
	Filing Date December 15, 2003		Group Art Unit	


Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MD	AQQQQ	Dillman et al. (1988), "Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients", Mol. Biother. 1(2):81-85.
	ARRRR	Dillman et al. (1994), "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies", Cancer Biotherapy 9(1):17-28.
	ASSSS	Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-148.
	ATTTT	Harlow and Lane (1988), "Antibodies: A laboratory manual", Cold Spring Harbor Laboratory, p139-243.
	AUUUU	Heston (1997), "Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase", Urology 49(3A):104-112.
	AVVVV	Horoszewicz et al. (1987), "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients", Anticancer Research 7(5B):927-936.
	AWWWW	Israeli et al. (1993), "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", Cancer Research 53(2):227-230.
	AXXXX	Israeli et al. (1994), "Expression of the Prostate-Specific Membrane Antigen", Cancer Research 54(7):1807-1811.
	AYYYY	Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-450.
	AZZZZ	Jain, R.K. (1990), "Vascular and interstitial barriers to delivery of therapeutic agents in tumors", Cancer and Metastasis Reviews 9(3):253-266.
	AAAAA	Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene", British Journal of Cancer 72:583-588.
	BBBBB	Leung et al. (1986), "Selection of a Monoclonal Antibody to a New Prostate Cancer Marker for In Vivo Clinical Trials", 6 th International Congress of Immunology, p516 (Abstract 4.15.19).
	ACCCC	Liu et al. (1997), "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium", Cancer Research 57(18):3629-3634.
	ADDDD	Liu, et al. (1998), "Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen", Cancer Research 58(18):4055-4060.
	AEEEE	Murphy et al. (1995), "Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement", The Prostate 26:164-168.
↓	AFFFF	Murphy et al. (1995), "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients", Anticancer Res. 15:1473-1480.

Examiner Signature /Minh Tam Davis/ (08/18/2006)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MD	AGGGGG	Murphy et al. (1996), "Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody", The Prostate 28(4):266-271.
	AHHHHH	Pinto et al. (1996), "Prostate-Specific Membrane Antigen: A Novel Folate Hydrolase in Human Prostatic Carcinoma Cells", Clinical Cancer Research 2(9):1445-1451.
	AIIIII	Rochon et al. (1994), "Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients", The Prostate 25(4):219-223.
	AJJJJJ	Schlom (1991), "Monoclonal antibodies: They're more and less than you think", Molecular Foundations of Oncology, ed. Broder, Williams & Wilkins, p95-134.
	AKKKKK	Silver et al. (1997), "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues", Clinical Cancer Research 3:81-85.
	ALLLLL	Su et al. (1995), "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", Cancer Research 55:1441-1443.
	AMMMMM	Troyer et al. (1994), "Subcellular Localization of the 7E11-C5 Prostate Specific Antigen", Proc. Am. Assoc. Cancer Research 35:283 (Abstract 1688).
	ANNNNN	Troyer et al. (1995), "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen", Urol Oncol 1:29-37.
	AOOOOO	Troyer et al. (1995), "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids", International Journal of Cancer 62(5):552-558.
	APPPPP	Troyer et al. (1997), "Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line", Prostate 30(4):232-242.
	AQQQQQ	Uria et al. (1997), "Prostate Specific Membrane Antigen in Breast Carcinoma", The Lancet 349(9065):1601.
	ARRRRR	Wang et al. (1988), "Monoclonal Antibody Assays for Prostatic Tumor", Immunol Ser 39:195-219.
	ASSSSS	Wright (1990), "Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5", Antibody Immunoconjugates and RadioPharmaceuticals 3:Abstract 193.
	ATTTTT	Wright et al. (1995), "Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues", Urol Oncol, 1:18-28.
↓	AUUUUU	Yang et al. (1998), "Alpha particle emitter therapy of micrometastases: ²¹³ Bi-J5 (anti-PSMA) treatment of LNCaP spheroids", Proceedings of the American Association for Cancer Research 39:440 (Abstract #2996).

Examiner Signature /Minh Tam Davis/ (08/18/2006)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-201001	Application No. 10/736,112
Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Jeffrey S. Ross	
		Filing Date December 15, 2003	Group Art Unit 3736

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							<input checked="" type="checkbox"/> Yes	<input checked="" type="checkbox"/> No
MD	AB	WO98/03873	01/1998	PCT				
MD	AC	EP 0 392 423 A2	10/1990	EPO			X (abst)	
MD	AD	EA 4634 B1	6/24/04	Eurasia			X (abst)	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MD	AE	Adsan et al., "Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence?", BJU International, 90:579-585 (2002)
MD	AF	Loric et al., "Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer", European Journal of Cancer, 37:1475-1481 (2001)
	AG	

Examiner Signature /Minh Tam Davis/ (08/18/2006)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)